Fidelis Capital Partners LLC Purchases 1,992 Shares of Johnson & Johnson (NYSE:JNJ)

Fidelis Capital Partners LLC raised its position in Johnson & Johnson (NYSE:JNJFree Report) by 17.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 13,181 shares of the company’s stock after acquiring an additional 1,992 shares during the period. Johnson & Johnson makes up about 0.7% of Fidelis Capital Partners LLC’s holdings, making the stock its 28th largest position. Fidelis Capital Partners LLC’s holdings in Johnson & Johnson were worth $2,052,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $27,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $37,000. Tower View Wealth Management LLC boosted its position in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC lifted its holdings in Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares during the period. Finally, VitalStone Financial LLC bought a new stake in Johnson & Johnson during the second quarter worth $48,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $156.76 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The firm has a market cap of $377.37 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53. The business’s fifty day moving average is $158.20 and its 200 day moving average is $158.73.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the previous year, the company posted $2.35 EPS. The firm’s revenue for the quarter was down 9.7% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Analysts Set New Price Targets

A number of brokerages recently commented on JNJ. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday, February 6th. Morgan Stanley dropped their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Read Our Latest Research Report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.